The data from clinical trials of GPR40 agonist TAK-875 has proved that hemoglobin A1C (HbA1c) levels in T2DM patients can be reduced significantly after treatment with TAK-875. The gene discussed is FFAR1; the disease is type 2 diabetes mellitus.